Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Healthcare ETF

72.14
+1.221.72%
Post-market: 72.200.0600+0.08%18:23 EDT
Volume:931.18K
Turnover:66.39M
Market Cap:4.05B
PE:6.50
High:72.22
Open:70.69
Low:70.69
Close:70.92
52wk High:74.59
52wk Low:59.47
Shares:56.10M
Float Shares:56.10M
Volume Ratio:0.94
T/O Rate:1.66%
Dividend:0.81
Dividend Rate:1.12%
EPS(TTM):11.10
EPS(LYR):3.06
ROE:6.01%
ROA:0.87%
PB:1.45
PE(LYR):23.58

Loading ...

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Reuters
·
Oct 08

Novartis announces FDA approval of Rhapsido for symptomatic dermographism

TIPRANKS
·
Oct 07

Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)

GlobeNewswire
·
Oct 07

Pharma Lobby Sues Trump Administration over Medicare Drug Price Cuts

Reuters
·
Oct 07

Eli Lilly is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Oct 07

What Eli Lilly Stock's First Line Jaypirca Approval Means For Shareholders

Simply Wall St.
·
Oct 07

Halozyme Therapeutics Shares up 2% After Court Win Against Merck to Block Subcutaneous Keytruda in Select Markets

THOMSON REUTERS
·
Oct 07

Micro-Cap Stock Veraxa Biotech is Down 96% This Year. Can Next-Gen Drug Testing Save It?

Dow Jones
·
Oct 07

Morgan Stanley Adjusts Price Target on Merck to $177 From $179

MT Newswires Live
·
Oct 07

AbbVie’s telisotuzumab adizutecan gets two FDA Breakthrough Therapy Designations

TIPRANKS
·
Oct 07

Tempus AI announces multi-year collaboration with Moderna, Merck

TIPRANKS
·
Oct 07

Halozyme announces Dutch court of the Hague found Merck infringed patents

TIPRANKS
·
Oct 07

AbbVie Says FDA Grants Breakthrough Therapy Status for ABBV-400 in Metastatic Colorectal Cancer

Reuters
·
Oct 07

Tempus Expands Multi-Year Collaboration with Moderna, Merck on V940 Melanoma Vaccine Commercialization Support

Reuters
·
Oct 07

Abbvie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations from the U.S. FDA for Crc and Nsclc

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Iv Version of Keytruda Remains Available and not Covered by Halozyme's Patent or Court Injunction

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Court Rejects Merck's Arguments That Ep622 Patent is Invalid

THOMSON REUTERS
·
Oct 07

Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda Sc in Multiple European Markets

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Court Orders Msd BV to Stop Keytruda Sc Manufacture and Sale in Eight European Countries

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Injunction Forbids Msd from Facilitating Infringement by Affiliates

THOMSON REUTERS
·
Oct 07